Arcus Biosciences Return on Tangible Equity 2017-2022 | RCUS
Current and historical return on tangible equity values for Arcus Biosciences (RCUS) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Arcus Biosciences Return On Tangible Equity Historical Data |
| Date |
TTM Net Income |
Tangible Equity |
Return on Tangible Equity |
| 2022-12-31 |
$-0.27B |
$0.66B |
-36.83% |
| 2022-09-30 |
$0.08B |
$0.70B |
10.37% |
| 2022-06-30 |
$0.07B |
$0.75B |
9.15% |
| 2022-03-31 |
$0.06B |
$0.80B |
8.32% |
| 2021-12-31 |
$0.05B |
$0.84B |
7.98% |
| 2021-09-30 |
$-0.28B |
$0.54B |
-48.21% |
| 2021-06-30 |
$-0.20B |
$0.61B |
-34.37% |
| 2021-03-31 |
$-0.17B |
$0.67B |
-31.40% |
| 2020-12-31 |
$-0.12B |
$0.50B |
-30.45% |
| 2020-09-30 |
$-0.09B |
$0.54B |
-27.54% |
| 2020-06-30 |
$-0.11B |
$0.43B |
-49.18% |
| 2020-03-31 |
$-0.10B |
$0.14B |
-55.96% |
| 2019-12-31 |
$-0.09B |
$0.16B |
-44.74% |
| 2019-09-30 |
$-0.08B |
$0.18B |
-38.51% |
| 2019-06-30 |
$-0.07B |
$0.20B |
-30.70% |
| 2019-03-31 |
$-0.06B |
$0.22B |
-22.99% |
| 2018-12-31 |
$-0.05B |
$0.24B |
-19.96% |
| 2018-09-30 |
$-0.05B |
$0.25B |
-22.15% |
| 2018-06-30 |
$-0.06B |
$0.26B |
-37.28% |
| 2018-03-31 |
$-0.06B |
$0.27B |
-56.06% |
| 2017-12-31 |
$-0.05B |
$0.15B |
-137.66% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$1.165B |
$0.112B |
|
Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company's product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in its Phase1 is a monoclonal antibody which potently and selectively blocks a protein called PD-1. AB154 is a monoclonal antibody which potently and selectively blocks a novel immune checkpoint called TIGIT. AB680, which is in its Phase1 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine within the tumor micro-environment. Arcus Biosciences is based in Hayward, CA.
|
